Henry Fuchs
Chief Tech/Sci/R&D Officer at BIOMARIN PHARMACEUTICAL INC.
Net worth: 17 M $ as of 2024-03-30
Profile
Currently, Henry J. Fuchs occupies the position of President-Worldwide Research & Development at BioMarin Pharmaceutical, Inc. Dr. Fuchs is also on the board of Mirati Therapeutics, Inc. In his past career he held the position of Independent Director at Ardea Biosciences, Inc., Chief Medical Officer & Executive Vice President at Onyx Pharmaceuticals, Inc. and Principal at Genentech, Inc. Dr. Fuchs received a doctorate from George Washington University and an undergraduate degree from Harvard University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-14 | 196,872 ( 0.10% ) | 17 M $ | 2024-03-30 |
Henry Fuchs active positions
| Companies | Position | Start |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 2009-02-28 |
Former positions of Henry Fuchs
| Companies | Position | End |
|---|---|---|
| MIRATI THERAPEUTICS | Director/Board Member | 2023-05-10 |
| GENOMIC HEALTH, INC. | Director/Board Member | 2019-11-07 |
Ardea Biosciences, Inc.
 Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Chief Executive Officer | 2005-05-31 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | 2008-11-30 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 1995-12-31 |
Training of Henry Fuchs
| Harvard University | Undergraduate Degree |
| George Washington University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Private companies | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
IntraBiotics Pharmaceuticals, Inc.
 IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Health Technology |
Genomic Health, Inc.
 Genomic Health, Inc. Medical SpecialtiesHealth Technology Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA. | Health Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Health Technology |
- Stock Market
- Insiders
- Henry Fuchs
